Abstract:Aim: This study aims to identify novel steroidal 5-alpha reductase (5AR) inhibitors using computational approaches. Objectives: The objective of this study is to exploit the steroidal nuclei for possible modifications by creating a library of 17-oximino-5-androsten-3-carboxamide derivatives and identify potent 5AR inhibitors based on docking and pharmacokinetic parameters. Background: Benign prostatic hyperplasia (BPH) is a condition of aged men that is characterized by lower urinary tract symptoms. Excessive production of dihydrotestosterone (DHT) from testosterone has been found to play a major role in its pathophysiology. Studies targeting the 5AR enzyme have so far resulted in the development of two clinically approved 5AR inhibitors. Methods: Atom-based three-dimensional-quantitative structure-activity relationship (3D-QSAR) models have been developed using a selected series of steroidal derivatives as 5AR inhibitors to elucidate the structural properties required for 5AR inhibitory activities. Further in‒silico studies (molecular docking and pharmacokinetic properties like adsorption, distribution, metabolism, and excretion) of 17- oximino-5-androsten-3-carboxamide derivatives have also been carried out to identify the binding orientation and protein-ligand interactions responsible for the exhibited activity and drug like properties. Results: The best 3D-QSAR model was generated using Partial Least Square method with an excellent correlation coefficient (R2, training set) of 0.882, standard deviation (SD) of 0.09, and a predicted coefficient (Q2, test set) of 0.814. Docking analysis indicated that the designed series of compounds have comparable binding affinity from -8.961 to -8.017 to the protein and suggested that hydrophobic and electrostatic moieties can have a key role in the inhibition mechanism. Conclusion: 3D-QSAR, molecular docking and pharmacokinetic studies indicated that 17-oximino-5- androsten-3-carboxamide derivatives could be studied further to provide a new strategy for the treatment of BPH.

The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH

Synthesis and Modeling of Novel Α-Aminoalkylphosphonate Ester Derivatives As Potent Inhibitors of Prostate-Specific Antigen; A Comparison Study

A Novel Asymmetric Synthesis of Cis-(3r, 4R)-N-(tert-butoxycarbonyl)-4-methyl-3-(methylamino) Piperidine

Structure-Based Drug Design of Diphenyl Α-Aminoalkylphosphonates As Prostate-Specific Antigen Antagonists.

Synthesis of 1-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-2-formyl Piperazine

Synthesis of Tert-Butyl-4-methyl-3-oxopiperidine-1-carboxylate

Structure-Based Design Of Tripeptide Derivatives Of α-Aminoalkylphosphonate Esters For Prostate-Specific Antigen Inhibition

Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer

Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer

Convenient Synthesis and Characterization of Novel 4-[2-ethoxy-5-(4-methyl-1-piperazinesulphonyl)benzamido]-3-isobutyl-1-methyl-1h-pyrazole-5-carboxamide: Key Precursor for Isobutyl Sildenafil

Isolation and Identification of Active Compounds on Benign Prostate Hyperplasia from Oiltea camellia Extract

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Amino polycarboxylic acids-modified abiraterone derivatives as potential injectable anti-prostate cancer agents

3D-QSAR, Molecular Docking and Pharmacokinetic Studies: In-Silico Approach to Search Novel Inhibitors of 5-Alpha Reductase for Treatment of Benign Prostatic Hyperplasia

Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists

Discovery of Pyridine Tetrahydroisoquinoline Thiohydantoin Derivatives with Low Blood-Brain Barrier Penetration As the Androgen Receptor Antagonists.

Discovery of 2-(1-(3-chloro-4-cyanophenyl)-1h-pyrazol-3-yl)acetamides As Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor

1-Benzyloxy-5-phenyltetrazole derivatives highly active against androgen receptor-dependent prostate cancer cells

Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells

Piperazine-Derived α1D/1A Antagonist 1- Benzyl-N- (3-(4- (2-Methoxyphenyl) Piperazine-1-yl) Propyl) -1H- Indole-2- Carboxamide Induces Apoptosis in Benign Prostatic Hyperplasia Independently of α1-Adrenoceptor Blocking

1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells